Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.

American journal of hematology - 1 Nov 2015

Sciumè Mariarita, Vincenti Daniele, Reda Gianluigi, Orofino Nicola, Cassin Ramona, Giannarelli Diana, Gaidano Gianluca, Rossi Davide, Cortelezzi Agostino

Abstract excerpt

Relapsed/refractory chronic lymphocytic leukemia (CLL) represents a clinical challenge, in particular when high risk gene mutations occur. In this setting, alemtuzumab was recognized to be effective. This retrospective study evaluates long-term efficacy and tolerability of low-dose alemtuzumab in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Receptor, Notch1

Share to Remission Induction

Share to Ribonucleoprotein, U2 Small Nuclear

Share to RNA Splicing Factors

Share to Vidarabine

Source

Identifiers

PMID: 26201283
DOI: 10.1002/ajh.24127

Genes

NOTCH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26201283-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.PMID 26201283Read ↗

Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.Semantic proximity Read ↗

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.Semantic proximity Read ↗

NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.Semantic proximity Read ↗

Understanding and managing ultra high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).Semantic proximity Read ↗

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.Semantic proximity Read ↗

Optimizing frontline therapy of CLL based on clinical and biological factors.Semantic proximity Read ↗

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.Semantic proximity Read ↗

Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia.Semantic proximity Read ↗

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.Semantic proximity Read ↗

Acalabrutinib in treatment-naive chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.